UK NEQAS Flow Cytometry Sample Quality Survey

As part of our ongoing commitment to quality improvement UK NEQAS for Leucocyte Immunophenotyping is keen to obtain the views of participants on the quality of samples issued in the flow cytometry programmes operated by this centre and acquire feedback on the continuing development of the Leukaemia Immunophenotyping programme. We would be extremely grateful if participants registered in the flow cytometry programmes could complete this survey, which can be accessed by clicking on the following link

 

https://www.surveymonkey.co.uk/r/UKNEQASLI_flow_cytometry_sample_quality_and_LI_Edu_A

 

 

Unfortunately, the survey cannot be saved prior to submission but we envisage that the survey should take approximately 10 minutes to complete.

 

All information submitted by participants will remain the property of UK NEQAS LI and will not be divulged to any other 3rd party. However, it may be presented in a generic form in presentations and/or publications.

Re-Registration for 2017/2018

There are 2 weeks remaining to re-register for 2017/18. Please click here and log in to your account to re-register.


For more information, please email admin@ukneqasli.co.uk

Changes to z score Limits

As a result of an internal review, we have taken the decision to adjust the performance monitoring limits for quantitative programmes.


These will be rolled out on an ongoing basis until all such quantitative programmes are amended.


Listed below are the current quantitative programmes where the changes have been made.  This will be updated as and when changes to any programmes are made and show the trial and date when the changes came into effect.

 

Programme Trial Effective From
BCR-ABL1 Major Quantification        161702 13/09/2016
Post SCT Chimerism Monitoring        161703 26/10/2016
Low Level Leucocyte Enumeration        161708 16/01/2017
CD34+ Stem Cell Enumeration        161705 23/01/2017

Immune Monitoring Alternative Technologies

161705 24/01/2017
Minimal Residual Disease for Acute Lymphoblastic Leukaemia        161704 24/01/2017
Immune Monitoring        161705 30/01/2017
Pilot Minimal Residual Disease in AML     161703  07/02/2017
Pilot Minimal Residual Disease in CLL        161703 13/02/2017
Leukaemia Immunophenotyping (Part 1)        161705 21/02/2017

 

The changes to the performance limits detailed below will be applicable to all quantitative programmes appearing in the above list unless otherwise specified.


• A result between 2.5 and -2.5 will now be classed as satisfactory


• A result between >2.5 and 3.5 or <-2.5 and -3.5 will be classed as an 'Action’ result. An ‘Action’ category highlights a potential issue to the laboratory and indicates that the laboratory should review. Two ‘Action’ results in a period of 3 samples would result in classification as a ‘Critical’


• A result above 3.5 or below -3.5 is considered to be a ‘critical’ result requiring immediate investigation by the laboratory


Please note that if you are a UK-based laboratory the relevant National Quality Assurance Advisory Panel will be automatically notified when a Critical level of performance is assigned. Non-UK laboratories are not notified to UK NQAAP’s.

Connect with us

UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) now has a Facebook page and a Twitter account. We will be posting important messages to these accounts relating to our schemes so please like or follow us, respectively.

We hope that these feeds will act as a useful eductational resource for participants and collaborators alike, collating interesting papers, conference info, videos and news stories in haemato-oncology. As we develop our online presence we hope to publish some of our own educational content. If you have any feedback or ideas as to content you would like us to include, please do not hesitate to get in touch.

Print Print | Sitemap

Follow Us Online!
Facebook Twitter LinkedIn Youtube

Disclaimer

Last updated 9th March 2017 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.